Y-Mabs Therapeutics Inc (NASDAQ:YMAB) concluded the trading at $11.88 on Wednesday, November 27, with a rise of 10.31% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $10.77 and 5Y monthly beta was reading 0.671 with its price kept floating in the range of $10.665 and $11.98 on the day. Considering stock’s 52-week price range provides that YMAB hit a high price of $20.90 and saw its price falling to a low level of $5.31 during that period. Over a period of past 1-month, stock came subtracting -19.40% in its value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
With its current market valuation of $532.10 million, Y-Mabs Therapeutics Inc is set to declare its quarterly results in December. Analysts are in estimates of -0.11 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -0.57 for current year with estimates of that growing to -0.49 in next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of 26.87M. They suggested that in the process company could generate revenue of as low as 24.84M which could climb up to 30M to hit a high. The average estimate is representing an increase of 15.00% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of 88.46M in current fiscal year, which will be 4.30% more from revenue generated by the company last year.
In contrast, when we review YMAB stock’s current outlook then short term indicators are assigning it an average of 100% Sell, while medium term indicators are categorizing the stock at an average of Hold. Long term indicators are suggesting an average of 100% Sell for it.
According to ratings assigned by 5 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 0 of them are recommending Y-Mabs Therapeutics Inc (YMAB) as a Hold, while 5 are in view that stock is a Buy. Recommendation by 0 analysts for the stock is an Underweight while number of those analysts who rated the stock as an Overweight is 0, whereas 0 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Overweight and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the YMAB stock which is currently positioned at 0. It further provides that stock’s current price level is -7.09% away from its 20-day simple moving average and is -12.24% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 43.82 while volatility remained at 8.38% over the past week which changes to 7.83% when measuring it over the past month. Beta is valued at 0.58, while measure of average true range or ATR is currently at 0.91. In predicting price targets of as low as $13 and as high as $24, analysts are in agreement on assigning the stock over the next 12 months average price target of $21.5. Stock’s current price level is -9.43% above from estimated low price target while it is -102.02% below the estimated high; and even if the YMAB’s share succeeded to reach the median price of $21.5, then the outlook of -80.98% could come to the excitement of the investors.
Having a second look at Y-Mabs Therapeutics Inc (NASDAQ:YMAB) provides that stock’s average daily trading volume for 3 months was 258.66K, while it jumped to 300320 when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 43.67 million.
The percentage of outstanding shares held by the insiders is 16.99% while it is 60.15% for the institutional holders. The figures also indicate that as of 2024-11-15, number of stock’s short shares was 3.63 million which implies a short ratio of 14.79. This shows down a 973.00 of Short Interest in company’s outstanding shares on the day. In November the standing of shares short improved as it was 4.25 million in the previous month. Addition of 74.19% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
